As Medscape UK’s foremost analyst of long-term disease management, Davenport illuminates the intersection of clinical outcomes and patient lived experiences. His work spans:
Successful pitches combine:
“We’re moving from treating disease states to caring for human beings.” – Davenport’s summation of modern medicine’s shift
Recent accolades include the 2024 European Medical Journalism Award for pediatric dermatology coverage.
Liam Davenport’s career began in broad healthcare journalism, but his focus sharpened as he recognized the critical need for nuanced coverage of chronic diseases. Early work at regional UK health publications laid the groundwork for his transition to Medscape UK, where he became a trusted voice in dermatology and gastroenterology. His 2024 analysis of dupilumab’s impact on pediatric growth patterns marked a turning point, blending clinical data with patient quality-of-life narratives[1][2].
“Whole-person care is so important...how do I take care of this human being?” – Stephen E. Lupe, PsyD, on Davenport’s IBD coverage[6]
Davenport’s 2024 EADV Congress report analyzed 16-week dupilumab outcomes across 120 patients. The piece stood out for correlating eczema severity scores with WHO height percentiles, demonstrating how biologic therapy could normalize growth trajectories. His interviews with parents highlighted the social stigma of growth delays, pushing clinicians to consider treatment timing[2][3].
This 2025 MDedge feature dissected a phase 2 trial of JAK inhibitor cream for oral lichen planus. Davenport emphasized the 68% reduction in pain scores versus placebo, contextualizing findings within the broader shift toward targeted topical therapies. His analysis included dermatologist concerns about long-term safety monitoring[6][9].
Covering the ECCO 2025 Congress, Davenport revealed how anxiety and sleep disturbances predicted IBD flares independently of biomarkers. The article featured a Cleveland Clinic psychologist advocating for integrated behavioral care models, challenging purely biomedical approaches[6].
Davenport prioritizes studies tracking outcomes beyond 24 weeks, particularly in pediatric populations. His dupilumab analysis[2] succeeded by comparing growth charts at baseline and 16-week intervals. Pitch comparative real-world evidence on growth/development metrics.
Articles like the IBD psychosocial study[6] demonstrate his focus on PROs. Successful pitches include validated quality-of-life instruments paired with clinical endpoints.
His ruxolitinib piece[9] used JAK/STAT pathway diagrams. Propose 3D molecular models or animated treatment mechanisms for complex therapies.
Davenport spotlights integrated approaches, as seen in his behavioral medicine interviews[6]. Pitch multidisciplinary programs with measurable outcomes.
While UK-focused, his work references WHO guidelines and EU regulatory decisions. Position pitches within international treatment disparities.
European Medical Journalism Award (2024) – Honored for advancing patient-centered reporting standards through growth metric analyses in pediatric dermatology. The jury noted Davenport’s “rare balance of statistical rigor and human impact narratives.”[5]
Guild of Health Writers Fellowship (2023) – Recognized contributions to demystifying biologic therapies. His fellowship paper proposed frameworks for communicating drug development risks to patients with low health literacy.[4]
At PressContact, we aim to help you discover the most relevant journalists for your PR efforts. If you're looking to pitch to more journalists who write on Health, here are some other real estate journalist profiles you may find relevant:
